Arena Pharmaceuticals (ARNA) 4.71 $ARNA Vivus' Qsymia

New Post Public Reply Private Reply Replies (0) Message Board

Mar 16, 2015 at 1:32 PM

Arena Pharmaceuticals (ARNA) 4.71 $ARNA

Vivus' Qsymia Breaks 3-Week Stagnancy, Could Start Upward Trend
Clinically Sound Investor - at Seeking Alpha - Mon Mar 16, 8:51AM CDT

OREX: 6.92 (-0.12), VVUS: 2.85 (+0.03), ARNA: 4.71 (-0.10)

Who Will Be Orexigen's Ex-U.S. Partner? My Bet Is On Takeda
Scientist on Stocks - at Seeking Alpha - Mon Mar 16, 7:27AM CDT

OREX: 6.92 (-0.12), ARNA: 4.71 (-0.10)

Orexigen - Contrave Scripts Rise Over 6%, But The Focus Is On Europe
Spencer Osborne - at Seeking Alpha - Sun Mar 15, 7:45PM CDT

OREX: 6.92 (-0.12), VVUS: 2.85 (+0.03), ARNA: 4.71 (-0.10)

Too Good to Be True? Proceed With Caution on These 2 Biotechs
Todd Campbell and Michael Douglass, The Motley Fool - Motley Fool - Sat Mar 14, 11:02AM CDT
Tune in to this health care edition of Industry Focus for a look at two small biotechs that sound exciting -- and may in fact prove to be the next big thing -- but which currently face enough challenges that most Fools probably won't want to rush in....
OREX: 6.92 (-0.12), PTLA: 41.44 (+0.74), NVO: 48.89 (+1.29), VVUS: 2.85 (+0.03), SNY: 48.71 (+1.64), MNKD: 5.47 (-0.04), ARNA: 4.71 (-0.10)

Vivus - Qsymia Scripts Pass 11,000 For First Time In 2015
Spencer Osborne - at Seeking Alpha - Fri Mar 13, 4:44PM CDT

OREX: 6.92 (-0.12), VVUS: 2.85 (+0.03), ARNA: 4.71 (-0.10)

Arena Pharmaceuticals Now Likely To Miss Q1 Estimates
Clinically Sound Investor - at Seeking Alpha - Fri Mar 13, 3:14PM CDT

ARNA: 4.71 (-0.10)

Arena - Belviq Sales Remain More Modest Than Needed, But A Silver Lining Is Showing
Spencer Osborne - at Seeking Alpha - Fri Mar 13, 3:03PM CDT

OREX: 6.92 (-0.12), VVUS: 2.85 (+0.03), ARNA: 4.71 (-0.10)

Orexigen - Stage Is Set For European Approval Decision On Anti-Obesity Drug
Spencer Osborne - at Seeking Alpha - Fri Mar 13, 9:44AM CDT

OREX: 6.92 (-0.12), VVUS: 2.85 (+0.03), ARNA: 4.71 (-0.10)

Bad News For Pfizer's Chantix May Be Good News For Arena's Belviq
Spencer Osborne - at Seeking Alpha - Thu Mar 12, 4:34PM CDT

PFE: 34.45 (+0.45), ARNA: 4.71 (-0.10)

Orexigen Should Pull Through The Current Bad Publicity
Clinically Sound Investor - at Seeking Alpha - Wed Mar 11, 1:05PM CDT

OREX: 6.92 (-0.12), VVUS: 2.85 (+0.03), ARNA: 4.71 (-0.10)

Orexigen - Contrave Sales Continue Up
Spencer Osborne - at Seeking Alpha - Wed Mar 11, 8:34AM CDT

OREX: 6.92 (-0.12), VVUS: 2.85 (+0.03), ARNA: 4.71 (-0.10)

Critical Alerts For Linn Energy, ACADIA Pharmaceuticals, Arena Pharmaceuticals, Sears Holdings and YY Released By InvestorsObserver
PR Newswire - Wed Mar 11, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for LINE, ACAD, ARNA, SHLD and YY.
ACAD: 33.83 (-0.62), YY: 51.49 (-0.30), SHLDZ: 190.00 (+13.50), LINE: 10.66 (-0.54), SHLD: 38.11 (-0.10), ARNA: 4.71 (-0.10)

Zacks Rank #5 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 11, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
BCS: 15.06 (+0.14), APEI: 32.10 (+0.15), ATRC: 19.60 (-0.13), ATEN: 4.31 (-0.01), ARNA: 4.71 (-0.10)

Biotech Equities Technical Updates -- Gilead Sciences, Arena Pharma, ACADIA Pharma, Halozyme Therapeutics, and Juno Therapeutics
PR Newswire - Wed Mar 11, 8:05AM CDT
Editor Note: For more information about this release, please scroll to bottom.
ACAD: 33.83 (-0.62), HALO: 16.02 (+0.09), GILD: 100.97 (+1.36), JUNO: 52.16 (+2.67), ARNA: 4.71 (-0.10)

Arena Scripts Still Slower Than Needed - Are Downgrades In The Future?
Spencer Osborne - at Seeking Alpha - Wed Mar 11, 7:26AM CDT

ARNA: 4.71 (-0.10)

Type 2 Diabetes Therapeutics Pipeline Review 2015 - Featuring Over 200 Companies
M2 - Wed Mar 11, 6:50AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jbq2zb/type_2_diabetes) has announced the addition of the "Type 2 Diabetes - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Type 2 Diabetes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 2 Diabetes and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Type 2 Diabetes Overview - Therapeutics Development - Type 2 Diabetes - Therapeutics under Development by Companies - Type 2 Diabetes - Therapeutics under Investigation by Universities/Institutes - Type 2 Diabetes - Pipeline Products Glance - Type 2 Diabetes - Products under Development by Companies - Type 2 Diabetes - Products under Investigation by Universities/Institutes - Type 2 Diabetes - Companies Involved in Therapeutics Development - Type 2 Diabetes - Therapeutics Assessment - Drug Profiles - Small Molecules to Inhibit CDK5 for Type 2 Diabetes - Drug Profile - Type 2 Diabetes - Recent Pipeline Updates - Type 2 Diabetes - Dormant Projects - Type 2 Diabetes - Discontinued Products - Type 2 Diabetes - Product Development Milestones - Appendix Companies Mentioned - ActogeniX NV - Addex Therapeutics Ltd - Advinus Therapeutics Ltd. - Aegis Therapeutics, LLC - AFFiRiS AG - AlbireoPharma - Alchemia Limited - Alize Pharma SAS - Allozyne, Inc. - AlphaMab Co., Ltd - Ambrx, Inc. - Amgen Inc. - Anchor Therapeutics, Inc. - AntriaBio, Inc. - Ardelyx, Inc. - Arena Pharmaceuticals, Inc. - Arisaph Pharmaceuticals, Inc. - Array BioPharma Inc. - Arrien Pharmaceuticals, LLC - Artery Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca PLC - AUS Bio Limited - Avaxia Biologics, Inc. - Bayer AG - Betagenon AB - Biocon Limited - Biodel Inc. - Biogenomics Limited - BioRestorative Therapies, Inc. For more information visit http://www.researchandmarkets.com/research/jb...2_diabetes
AMBX: (), AZN: 68.87 (+1.52), AMGN: 161.88 (+7.62), BIOD: 1.42 (+0.02), ARNA: 4.71 (-0.10), ARRY: 8.20 (+0.05)

Arena: Belviq's Steady Growth Points To More Total Prescriptions Highs
Clinically Sound Investor - at Seeking Alpha - Tue Mar 10, 2:35PM CDT

OREX: 6.92 (-0.12), VVUS: 2.85 (+0.03), ARNA: 4.71 (-0.10)

Does Reading Seeking Alpha Really Help Beat The Market? A 5-Year Meta-Analysis
Force Majeure - at Seeking Alpha - Tue Mar 10, 11:47AM CDT

BOFI: 94.55 (+1.55), NFLX: 418.80 (-19.60), MU: 28.33 (-0.39), TSLA: 192.53 (+3.85), SPY: 207.92 (+2.09), VVUS: 2.85 (+0.03), BIOD: 1.42 (+0.02), ARNA: 4.71 (-0.10)

Novo Nordisk Readies For Saxenda Launch - Investors Need To Keep Expectations Realistic
Spencer Osborne - at Seeking Alpha - Tue Mar 10, 1:21AM CDT

OREX: 6.92 (-0.12), NVO: 48.89 (+1.29), VVUS: 2.85 (+0.03), ARNA: 4.71 (-0.10)

Arena - Belviq Ads Slow Substantially - Eisai Promises Seem To Be Fading
Spencer Osborne - at Seeking Alpha - Tue Mar 10, 1:07AM CDT

OREX: 6.92 (-0.12), VVUS: 2.85 (+0.03), ARNA: 4.71 (-0.10)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Duke Energy's Cooling Tips Amid Florida Cold Front

Weather Whiplash in Florida Prompts Energy Tips Florida's residents are in for a gust of chilly air as a cold front sweeps across the state, sending temperatures plummeting from the balmy 80s to brisk 30s and 40s in northern pockets. Central Florida ain't missing out on the chill either, expecting to dip a good dozen degrees below its usual seasonal warmth. Heads up,...

MV Transportation Celebrates Leadership Nomination for FTA

MV Throws Support Behind Aesch for FTA Role In this wild world where public transit feels the heat from financial burdens, MV Transportation's recent move to support Mark Aesch for the Federal Transit Administration's top spot isn’t just a nod of approval—it's a full-blown trumpet blast. They're not just doling out a basic endorsement here; they're practically waving...

Terra Kaffe's Big Win with Oprah's Endorsement

Terra Kaffe Hits the Jackpot with Oprah Sometimes, destiny has a way of handing out golden tickets, and for Terra Kaffe, receiving a nod from Oprah Winfrey's revered list of Favorite Things for 2026 is nothing short of that. I mean, you can't underestimate the pull Mrs. O has. Her endorsement isn’t just another celebrity pat-on-the-back, it’s a megaphone blaring...

First Horizon's $25M Bet: New Center Transforms Houston

New Markets Tax Credits: A Game Changer First things first, if you're thinking this is some typical charitable write-off, think again. First Horizon Bank (NYSE: FHN) is deep in the mix of something pretty transformative in the world of finance and community support. They're not just throwing money at a problem and hoping it sticks. Nope, we're talking real strategy with a...

Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

The Melt Expands with Key Texas Franchise Deal

Throwing Down the Gauntlet: The Melt Expands If there's one thing I've learned after decades watching these restaurant chains multiply like rabbits it’s this: when a veteran gets involved, you perk up. The Melt has done just that by roping in Syed Ahmad—a name that actually means something in this game—to open eight new locations in the Lone Star State. It isn't...

Innovative Rotating Kitchen Organizer Up for Licensing

Dusting Off the Corners: A Fresh Spin on Kitchen Storage Just when you think there's nothing new under the sun when it comes to storing your kitchen gadgets, here comes an invention straight out of Billings, Montana. It's called The Rotating Kitchen Organizer, a nifty contraption that's all set to turn those dead corners into prime real estate. How many times have we...

Euroandinos Paita Closes Consent for 2037 Notes

Port Strategy and Financial Implications Terminales Portuarios Euroandinos Paita S.A., nestled in the Peruvian transport sector, has been tight-rope walking through its debt landscape. Announcing a successful consent solicitation on November 13, 2026, they've taken a significant step towards reconfiguring their long-term financing game. This puppet show of paperwork...

SOCSA: The Future of Safety in Confined Spaces?

Autonomous Tech Meets Safety Regulations Some days innovation hits like a ton of bricks, and here we go again—this time with a gizmo aiming to shake up the safety game in confined spaces. Enter the SOCSA, the Self Operating Confined Space Attendant, designed by a seasoned agriculture worker who's had a ringside seat to enough OSHA rule breaches to fill a book. But ain't...

Maritime Safety Urged After New Orleans Vessel Incident

The Mississippi River saw a bit of drama near the Port of New Orleans when a river cruise turned into an unexpected rescue operation. Listen up, because incidents like this bring maritime safety right to the forefront; we can't ignore the waters that shape our daily lives here in the Big Easy. Navigating the Waters Safely Some 150 souls found themselves in a pickle when...